Table 1 Summary of model settings and input parameters

General population characteristics

 Age(years)

55

Assumption

General analysis settings

 Cycle length

6 months

-

 Time horizon

Lifetime

-

 Discount rate

4.5%

[17]

 Market share in patients with T-score decrease (Denosumab)

50.9%

IQVIA(2021, Q3)

 Market share in patients with T-score decrease (BP/SERM)

49.1%

IQVIA(2021, Q3)

T-score Transition Probability (per cycle)

 From Starting state^a to T-score decrease (0–3 years)^b

0.000

0.822

[12, 21]

 From Starting state^a to T-score decrease (after 3 years)^c

0.822

0.822

[12]

 From Starting state^a to T-score increase

0.108

0.000

[12]

 From T-score decrease to T-score increase

0.033

0.033

[12]

Fracture probability^d(per cycle)

 Starting state^a

0.004

0.013

[10, 12]

 T-score decrease

0.006

0.019

 T-score increase (-2.5 < T-score≤-2)

0.004

0.013

 T-score increase (-2.0 < T-score)

0.002

0.007

Non-vertebral fracture

 Starting state^a

0.013

0.016

[10, 12]

 T-score decrease

0.015

0.018

 T-score increase (-2.5 < T-score≤-2)

0.013

0.016

 T-score increase (-2.0 < T-score)

0.009

0.011

Costs (per cycle, KRW)

Drug costs

 Denosumab

177,650

HIRA, Weighted average drug price list, 2021

 BP(Oral)

125,112

 BP(IV)

107,296

 SERM

120,050

Administration costs

 Denosumab

4,843

HIRA, Fee-for-service price, 2022

 BP(Oral)

20,226

 BP(IV)

2,422

 SERM

45,705

Fracture treatment costs

 Vertebral fracture

2,717,095

[26]

 Non-vertebral fracture

2,684,098